Reflux disease and Barrett's esophagus

Endoscopy

Volumn 28, Issue 1, 1996, Pages 13-21

  Falk, G W ^a   Richter, J E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

BARRETT ESOPHAGUS; CANCER RISK; CELL PROLIFERATION; COLUMNAR EPITHELIUM; ENDOSCOPIC BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; HUMAN TISSUE; LASER SURGERY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW;

EID: 0029985203     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1005413     Document Type: Review

References (84)

1. Spechler SJ, Goyal RK: Barrett's esophagus. N Engl J Med 1986; 315: 362-371.
2. Cameron AJ, Zinsmeister AR, Ballard DJ, et al.: Prevalence of columnar-lined (Barrett's) esophagus. Gastroenterology 1990; 99: 918-922.
3. Cameron AJ, Tomboy CT: Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103: 1241-1245.
4. Mann, NS, Tsai MF, Nair PK: Barrett's esophagus in patients with symptomatic reflux esophagitis. Am J Gastroenterol 1989; 84: 1494-1496.
5. Johnson DA, Winters C, Spurling TJ, et al.: Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 1987; 91: 23-27.
6. Paull A, Trier JS, Dalton MD, et al.: The histologic spectrum of Barrett's esophagus. N Engl J Med 1976; 295: 476-480.
7. Weinstein WM, Bogoch ER, Bowes KL: The normal lower esophageal mucosa: a histologic reappraisal. Gastroenterology 1975; 68: 40-44.
8. Dent J, Bremner CG, Collen MJ, et al.: Working party report to the World Congresses of Gastroenterology, Sydney 1990. J Gastroenterol Hepatol 1991; 6: 1-22.
9. Spechler SJ, Zeroogian JM, Antonioli DA, et al.: Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994; 344: 1533-1536.
10. Jass JR: Role of intestinal metaplasia on the histogenesis of gastric carcinoma. J Clin Pathol 1980; 33: 801-810.
11. Bremner CG, Lynch VP, Ellis FH: Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 1970; 68: 209-216.
12. Li H, Walsh TN, O'Dowd C, et al.: Mechanisms of columnar metaplasia and squamous regeneration in experimental Barrett's esophagus. Surgery 1994; 115: 176-181.
13. Singh P, Taylor RH, Colin-Jones DG: Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present. Am J Gastroenterol 1994; 89: 349-356.
14. Neumann CS, Cooper BT: 24-hour ambulatory oesophageal pH monitoring in uncomplicated Barrett's metaplastic epithelium. Gut 1994; 35: 1352-1355.
15. Collen MJ, Johnson DA, Sheridan MJ: Basal acid output and gastric acid hypersecretion in gastroesophageal reflux disease: correlation with ranitidine therapy. Dig Dis Sci 1994; 39: 410-417.
16. Mulholland MW, Reid BJ, Levine DS, et al.: Elevated gastric acid secretion in patients with Barrett's esophagus. Dig Dis Sci 1989; 34: 1329-1335.
17. Attwood SEA, DeMeester TR, Bremner CG, et al.: Alkaline gastroesophageal reflux: implications in the development of complications in Barrett's columnar-lined lower esophagus. Surgery 1989; 106: 764-770.
18. Champion G, Richter JE, Vaezi MF, et al.: Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994; 107: 747-754.
19. Gillen P, Keeling P, Byrne PJ, et al.: Experimental columnar metaplasia in the canine oesophagus. Br J Surg 1988; 75: 113-115.
20. Sartori S, Nielsen I, Indelli M, et al.: Barrett esophagus after chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF): an iatrogenic injury? Ann Intern Med 1991; 114: 210-211.
21. Peters FT, Sleijfer DT, Van Imhoff GW, et al.: Is chemotherapy associated with development of Barrett's esophagus? Dig Dis Sci 1993; 5: 923-926.
22. Spechler EJ: Barrett esophagus: a sequela of chemotherapy [editorial]. Ann Intern Med 1991; 114: 243-244.
23. 2 blockers. J Clin Gastroenterol 1987; 9: 139-141.
24. Wesdorp IC, Bartelsman J, Schipper ME, et al.: Effect of long-term treatment with cimetidine and antacids in Barrett's esophagus. Gut 1981; 22: 724-727.
25. Sampliner RE, Garewal HS, Fennerty MB, et al.: Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci 1990; 35: 93-96.
26. Devière J, Buset M, Dumoncleau JM, et al.: Regression of Barrett's epithelium with omeprazole [letter]. N Engl J Med 1989; 320: 1497-1498.
27. Gore S, Healey CJ, Sutton R, et al.: Regression of columnar-lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7: 623-628.
28. Sampliner RE: Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994; 89: 1844-1848.
29. Katzka DA, Castell DO: Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 989-991.
30. Kim SL, Waring JP, Spechler SJ, et al.: Diagnostic inconsistencies in Barrett's esophagus. Gastroenterology 1994; 107: 945-949.
31. Kim R, Baggott BB, Rose S, et al.: Quantitative endoscopy: precise computerized measurement of metaplastic epthelial surface area in Barrett's esophagus. Gastroenterology 1995; 108: 360-366.
32. Savanna V, Mela GS, Zentilin P, et al.: Once or twice daily doses of proton pump inhibitor in treating Barrett's esophagus? [Letter]. Am J Gastroenterol 1995; 90: 845-846.
33. Sampliner RE: Partial regression of Barrett's esophagus: an inadequate endpoint. Am J Gastroenterol 1993; 88: 2092-2094.
34. Brand DL, Ylvisaker JT, Gelfand M, et al.: Regression of columnar esophageal (Barrett's) epithelium after anti-reflux surgery. N Engl J Med 1980; 302: 844-848.
35. Williamson WA, Ellis FH, Gibb SP, et al.: Effect of antireflux operation on Barrett's mucosa. Ann Thorac Surg 1990; 49: 537 -542.
36. Sampliner RE, Hixson LJ, Fennerty ME, et al.: Regression of Barrett's esophagus by laser ablation in an anacid environment. Dig Dis Sci 1993; 38: 365-368.
37. Brandt LJ, Kauvar DR: Laser-induced transient regression of Barrett's epithelium. Gastrointest Endosc 1993; 38: 619-622.
38. Berenson MM, Johnson TD, Markowitz NR, et al.: Restoration of squamous mucosa after ablation of Barrett's epithelium. Gastroenterology 1993; 104: 1686-1691.
39. Falk GW: Barrett's esophagus. Gastrointest Endosc Clin North Am 1994; 4: 773-789.
40. Spechler SJ, Robbins AH, Rubins HB, et al.: Adenocarcinoma and Barrett's esophagus: an overrated risk? Gastroenterology 1984 87: 927-933.
41. Kahrilas P: It's not the American way - yet [editorial]. Am J Gastroenterol 1994; 89: 657-658.
42. Cameron AJ, Ott BJ, Payne WS: The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-859.
43. Pera M, Cameron AJ, Trastek VF, et al.: Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-513.
44. Clark GW, Smyrk TC, Burdiles P, et al.: Is Barrett's metaplasia the source of adenocarcinoma of the cardia. Arch Surg 1994; 129: 609-614.
45. Cameron AJ, Lomboy CT, Pera M, et al.: Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995; 109: 1541-1546.
46. Gray MR, Donnelly RJ, Kingsnorth AN: The role of smoking and alcohol in metaplasia and cancer risk in Barrett's columnar lined oesophagus. Gut 1993; 34: 727-731.
47. Iftikhar SY, James PD, Steele RJC, et al.: Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33: 155-158.
48. McArdle JE, Lewin KJ, Randall G, et al.: Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Human Pathol 1992; 23: 479-482.
49. Chow WH, Finkle WD, McLaughlin JK, et al.: The relation of gastroesophageal reflux disease and its treatment to adenocarcinoma of the esophagus and gastric cardia. J Am Med Assoc 1995; 274: 474-477.
50. Wang HH, Hsieh CC, Antonioli DA: Rising incidence rate of esophageal adenocarcinoma and use of pharmaceutical agents that relax the lower esophageal sphincter. Cancer Causes Control 1994; 5: 573-578.
51. Reid BJ, Sanchez CA, Blount PL, et al.: Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993; 105: 119-129.
52. Gray MR, Hall PJ, Nash J, et al.: Epithelial proliferation of Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology 1992; 103: 1769-1776.
53. Hameeteman W, Tytgat GNJ, Houthoff HJ, et al.: Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-1256.
54. Reid BJ, Blount PL, Rubin CE, et al.: Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992; 102: 1212-1219.
55. Rice TW, Falk CW, Achkar E, et al.: Surgical management of high-grade dysplasia in Barrett's esophagus. Am J Gastroentero; 1993; 88: 1832-1836.
56. Levine DS, Haggitt RC, Blount PL, et al.: An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105: 40-50.
57. Reid BJ, Weinstein WM, Lewin KJ, et al.: Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988; 94: 90-91.
58. Krishnadath KK, van Blankenstein M, Tilanus HW: Prognostic value of p53 in Barrett's esophagus. Eur J Gastroenterol Hepatol 1995; 7: 81-84.
59. Flejou JF, Potet F, Muzeau F, et al.: Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J Clin Pathol 1993; 46: 330-333.
60. Rice TW, Goldblum JR, Falk GW, et al.: P53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. Thorac Cardiovasc Surg 1994; 108: 1132-1137.
61. Ramel S, Reid BJ, Sanchez CA, et al.: Evaluation of p53 protein expression in Barrett's epithelium by two-parameter flow cytometry. Gastroenterology 1992; 102: 1220-1228.
62. Hardwick RH, Shepherd NA, Moorghen M, et al.: Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut 1994; 35: 764-768.
63. Younes M, Lebovitz RM, Lechago LV, et al.: p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993; 105: 1637-1642.
64. Flejou JF, Paraf F, Potet F, et al.: P53 protein expression in Barrett's adenocarcinoma: a frequent event with no prognostic significance. Histopathology 1994; 24: 487-489.
65. Spechler SJ: Endoscopic surveillance for patients with Barrett's esophagus: does the cancer risk justify the practice? [Editorial]. Ann Intern Med 1987; 106: 902-904.
66. Streitz JM, Andrews CW, Ellis FH: Endoscopic surveillance of Barrett's esophagus: does it help? J Thorac Cardiovasc Surg 1993; 105: 383-388.
67. Peters JH, Clark GW, Ireland AP, et al.: Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. Thorac Cardiovasc Surg 1994; 108: 813-822.
68. Levine DS, Reid BJ: Endoscopic biopsy technique for acquiring larger mucosal samples. Gastrointest Endosc 1991; 37: 332-337.
69. Reid BJ, Haggitt RC, Rubin CE: Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988; 19: 166-178.
70. Provenzale D, Kemp JA, Arora S, et al.: A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 670-680.
71. Achkar E, Carey W: The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol 1988; 83: 291-294.
72. Geisinger KR: Endoscopic biopsies and cytologic brushings of the esophagus are diagnostically complementary. Am J Clin Pathol 1995; 103: 295-299.
73. Robey SS, Hamilton SR, Gupta PK, et al.: Diagnostic value of cytopathology in Barrett esophagus and associated carcinoma. Am J Clin Pathol 1988; 89: 493-498.
74. Geisinger KR, Teot LA, Richter JE: A comparative cytopathologic, histologic study of atypia, dysplasia, and adenocarcinoma in Barrett's esophagus. Cancer 1992; 69: 8-16.
75. Shu YJ: Cytopathology of the esophagus. Acta Cytol 1983; 27: 7-16.
76. Chittajallu RS, Falk GW, Richter JE, et al.: Balloon cytology for the detection and surveillance of Barrett's esophagus [abstract]. Gastroenterology 1995; 108: A71.
77. Spechler SJ: Barrett's esophagus: what's new and what to do [editorial]. Am J Gastroenterol 1988; 84: 220-223.
78. Pera M, Trastek VF, Carpenter HA, et al.: Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy? Ann Thorac Surg 1992; 54: 199-204.
79. Srivastava AK, Vanagunas A, Kammel P, et al.: Endoscopic ultrasound in the evaluation of Barrett's esophagus: a preliminary report. Am J Gastroenterol 1994; 89: 2192-2195.
80. Folk GW, Catalano MF, Sivak MV, et al.: Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia. Gastrointest Endosc 1994; 40: 207-212.
81. Overholt B, DeNovo RC, Panjehpour M, et al.: A centering balloon for photodynamic therapy of esophageal cancer tested in a canine model. Gastrointest Endosc 1993; 39: 782-787.
82. Lightdale CJ: Photodynamic therapy: a new light on Barrett's esophagus [editorial]. Gastrointest Endosc 1995; 42: 96-98.
83. Laukka MA, Wang KK: Initial results using low-dose photodynamic therapy in the treatment of Barrett's esophagus. Gastrointest Endosc 1995; 42: 59-63.
84. Overholt B, Panjehpour M: Barrett's esophagus: photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa, and treatment of superficial esophageal cancer. Gastrointest Endosc 1995; 42: 64-70.